ClinicalTrials.Veeva
Menu

Find clinical trials for Kidney Disease in Baltimore, MD

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Kidney Diseases
Chronic Renal Insufficiency
Chronic Kidney Failure
IGA Glomerulonephritis
Renal Cell Carcinoma
Renal Insufficiency
Carcinoma

Kidney Disease trials near Baltimore, MD, USA:

A Phase 2 Study of MZE829 in Adults with APOL1 Kidney Disease

This is purpose of this study is to evaluate the safety, tolerability, and effect on Albuminuria of MZE829 in Adults with APOL1 Kidney Disease...

Enrolling
Proteinuric Kidney Disease
Drug: MZE829

Phase 2

Maze Therapeutics

Arlington, Virginia, United States and 21 other locations

will be conducted to assess the safety and tolerability of ferric citrate in pediatric participants with hyperphosphatemia related to chronic kidney...

Enrolling
Hyperphosphatemia Related to Chronic Kidney Disease
Drug: ferric citrate

Phase 3

Keryx Biopharmaceuticals

Baltimore, Maryland, United States and 12 other locations

The purpose of this study is to assess the efficacy and safety of AZD2373 in participants diagnosed with APOL1-Mediated Kidney Disease...

Enrolling
APOL1-Mediated Kidney Disease
Combination Product: Placebo
Device: APOL1 Genotyping Clinical Trial Assay

Phase 2

AstraZeneca
AstraZeneca

Bethesda, Maryland, United States and 31 other locations

is to evaluate the effect of tolvaptan on the need for renal replacement therapy in pediatric subjects with autosomal recessive polycystic kidney...

Enrolling
Autosomal Recessive Polycystic Kidney Disease (ARPKD)
Drug: Tolvaptan (OPC-41061)

Phase 3

Otsuka
Otsuka

Baltimore, Maryland, United States and 17 other locations

The main objective of this study is to evaluate the safety, efficacy and pharmacokinetics of paricalcitol oral solution in pediatric participants of...

Enrolling
Chronic Kidney Disease (CKD)
Secondary Hyperparathyroidism (SHPT)
Drug: Paricalcitol

Phase 3

AbbVie
AbbVie

Washington, District of Columbia, United States and 13 other locations

purpose of the study is to evaluate the efficacy, safety, and tolerability of Inaxaplin (IXP) in participants with proteinuric APOL1- mediated kidney...

Enrolling
Proteinuric Kidney Disease
Drug: Inaxaplin

Phase 2

Vertex Pharmaceuticals
Vertex Pharmaceuticals

Silver Spring, Maryland, United States and 13 other locations

The purpose of this study is to determine whether vonsetamig will safely decrease anti-HLA antibodies to allow for kidney transplantation.Vo...

Enrolling
Chronic Kidney Disease (CKD)
Drug: Vonsetamig

Phase 1, Phase 2

Regeneron Pharmaceuticals
Regeneron Pharmaceuticals

Baltimore, Maryland, United States and 8 other locations

To assess the impact of RGLS8429 on height-adjusted total kidney volume (htTKV)* To characterize the pharmacokinetic (PK) properties of RGLS...

Enrolling
Polycystic Kidney, Autosomal Dominant
Autosomal Dominant Polycystic Kidney Disease
Drug: Placebo
Drug: RGLS8429

Phase 1

Regulus Therapeutics

Baltimore, Maryland, United States and 27 other locations

to evaluate efficacy, safety and tolerability of treatment with zibotentan/dapagliflozin and dapagliflozin alone in participants with chronic kidney...

Active, not recruiting
Chronic Kidney Disease With High Proteinuria
Drug: Dapagliflozin
Drug: Zibotentan/Dapagliflozin

Phase 3

AstraZeneca
AstraZeneca

Silver Spring, Maryland, United States and 295 other locations

compared with dapagliflozin alone on patients with chronic kidney disease (CKD) and albuminuria. This study will evaluate the effec...

Active, not recruiting
Chronic Kidney Disease
Drug: Dapagliflozin 10 mg and matching placebo for balcinrenone/dapa gliflozin
Drug: Balcinrenone/dapagliflozin 40 mg/10 mg and matching placebo for dapagliflozin 10 mg

Phase 2

AstraZeneca
AstraZeneca

Annapolis, Maryland, United States and 93 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems